First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon
Calliditas Therapeutics announced the enrollment of the first patient in the confirmatory part of the Phase 3 NefIgArd trial in China, facilitated by Everest Medicines. The trial's Part A, involving 200 patients, completed recruitment in December 2019, with topline data expected in Q4 2020. The ongoing Part B aims to recruit an additional 160 patients to validate the proteinuria surrogate marker. Successful results could lead to regulatory approvals in the US and Europe. This trial addresses significant unmet medical needs in Asia.
- First patient in China enrolled in Phase 3 NefIgArd trial, expanding trial reach.
- Completion of Part A recruitment with 200 patients, topline data expected in Q4 2020.
- Potential regulatory approval in US and Europe based on successful data.
- None.
STOCKHOLM, Sept. 8, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines.
Following IND approval by the NMPA in December of 2019 and subsequent approval by Human Genetic Resources Administration of China (HGRAC), the first patient in China has now been randomized in the Phase 3 NefIgArd trial. The first patient in NeflgArd was randomized by Calliditas in November 2018, and in December 2019 Calliditas announced the full recruitment of the 200 patients required for regulatory submission (Part A). Topline data for these 200 subjects is targeted for Q4 of 2020, which subject to positive data will form the basis for regulatory approval and market access in the US and Europe. The study has continued to recruit an additional 160 patients in order to complete the confirmatory part (Part B) of the trial, which relates to the validation of the surrogate marker, proteinuria. Everest Medicines is contributing to the recruitment of these 160 patients, based on the roll-out across centers in China.
"We are very pleased to now have the first patient from mainland China enrolled into the NefIgArd trial. As this disease represents a significant unmet need in Asia, we are excited that Everest Medicines have achieved this milestone, which supports the goal of completing recruitment before the end of the year," said Renée Aguiar-Lucander, CEO of Calliditas Therapeutics.
For further information, please contact:
Renée Aguiar-Lucander
CEO
Calliditas
Email: renee.lucander@calliditas.com
Mikael Widell
Investor Relations
Tel.: +46-703-11-99-60
email: Mikael.widell@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on September 8, 2020 at 08:00 a.m. CET.
About Calliditas
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (ticker: CALTX) and the Nasdaq Global Select Market (ticker: CALT). Visit www.calliditas.com for further information.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Calliditas' strategy, business plans and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas'' business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, and other risks identified in the section entitled "Risk Factors" Calliditas' reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas'' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/first-patient-in-china-enrolled-in-clinical-phase-3-study-nefigard-with-lead-candidate-nefecon-301125284.html
SOURCE Calliditas Therapeutics
FAQ
What is the NefIgArd Phase 3 trial for Calliditas (CALT)?
What are the implications of the first patient enrolled in China for CALT?
When is topline data expected for the NefIgArd trial?
How many patients are being recruited for the confirmatory part of the NefIgArd trial?
What is the significance of the NefIgArd trial for the market?
